Immuneering Corporation (IMRX) Reports In-Line Q2 EPS

Immuneering Corporation (NASDAQ: IMRX) reported Q2 EPS of ($0.27), in-line with the analyst estimate of ($0.27).

For earnings history and earnings-related data on Immuneering Corporation (IMRX) click here.

You May Also Be Interested In

• Yen Jumps More Than 1% To Trade At 158.22 Per Us Dollar
• StoneX Reiterates Buy Rating on DraftKings Inc. (DKNG)
• Rex American Resources Corp. (REX) Tops Q2 EPS by 64c